Baird Maintains Outperform on Astrana Health, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

Baird analyst Michael Ha maintains Astrana Health (NASDAQ:ASTH) with a Outperform and raises the price target from $37 to $40.